IDEAS home Printed from https://ideas.repec.org/a/spr/pharmo/v7y2023i3d10.1007_s41669-023-00404-3.html
   My bibliography  Save this article

A Cross-Indication Budget Impact Model of Secukinumab for the Treatment of Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis in Italy

Author

Listed:
  • Paolo Angelo Cortesi

    (University of Milan-Bicocca)

  • Carla Fornari

    (University of Milan-Bicocca)

  • Paolo Gisondi

    (University of Verona)

  • Florenzo Iannone

    (University of Bari, Policlinico)

  • Ippazio Cosimo Antonazzo

    (University of Milan-Bicocca)

  • Elisabetta Aloisi

    (Novartis Farma SpA)

  • Martina Fiocchi

    (Novartis Farma SpA)

  • Daniela Ritrovato

    (Novartis Farma SpA)

  • Lorenzo Giovanni Mantovani

    (University of Milan-Bicocca
    IRCCS Multimedica)

Abstract

Background Recent developments improved outcomes in patients with autoimmune diseases. Biologics were approved as first-line treatment in selected naïve patients with plaque psoriasis (PsO), psoriatic arthritis (PsA), ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA). Among them, secukinumab was most recently approved for treatment of active nr-axSpA in adults. In this work, we assessed the budget impact of new secukinumab treatment options in the Italian market. Methods A cross-indication budget impact model was designed to estimate the effects of adding secukinumab in the Italian market from the National Health System perspective over a 3-year period. The model included all adults with PsO, PsA, AS and nr-axSpA, treated with biologics or biosimilars. It compared costs between two scenarios, secukinumab availability or absence, for the four diseases combined and taken individually. A sensitivity analyses was conducted. Results There were 68,121 adult patients treated with biologics in 2021 and 68,341 in 2023. The budget impact analysis (BIA) on all indications showed a cost reduction of €33.7 million (− 1.5%) over 3 years with the introduction of secukinumab. PsA patients had the highest saving (− €34.9 million), followed by PsO patients (− €7.8 million). Cost saving in PsO patients was balanced by increased budget reported in AS patients (+ €8.0 million). In nr-axSpA patients, secukinumab reported no significant budget increase (+ 1.0%). Conclusion This BIA accounted for the new indication of secukinumab in nr-axSpA patients, reporting no significant changes in the required budget and adding an effective treatment option. Considering all indications, secukinumab is a sustainable treatment option.

Suggested Citation

  • Paolo Angelo Cortesi & Carla Fornari & Paolo Gisondi & Florenzo Iannone & Ippazio Cosimo Antonazzo & Elisabetta Aloisi & Martina Fiocchi & Daniela Ritrovato & Lorenzo Giovanni Mantovani, 2023. "A Cross-Indication Budget Impact Model of Secukinumab for the Treatment of Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis in Italy," PharmacoEconomics - Open, Springer, vol. 7(3), pages 405-416, May.
    • Handle: RePEc:spr:pharmo:v:7:y:2023:i:3:d:10.1007_s41669-023-00404-3
    DOI: 10.1007/s41669-023-00404-3
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s41669-023-00404-3
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1007/s41669-023-00404-3?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Roxanne Cooksey & Muhammad J Husain & Sinead Brophy & Helen Davies & Muhammad A Rahman & Mark D Atkinson & Ceri J Phillips & Stefan Siebert, 2015. "The Cost of Ankylosing Spondylitis in the UK Using Linked Routine and Patient-Reported Survey Data," PLOS ONE, Public Library of Science, vol. 10(7), pages 1-17, July.
    2. Lucia Sara D’Angiolella & Paolo Angelo Cortesi & Alessandra Lafranconi & Mariangela Micale & Sveva Mangano & Giancarlo Cesana & Lorenzo Giovanni Mantovani, 2018. "Cost and Cost Effectiveness of Treatments for Psoriatic Arthritis: A Systematic Literature Review," PharmacoEconomics, Springer, vol. 36(5), pages 567-589, May.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Jeong Seok Lee & Baek-Lok Oh & Hee Young Lee & Yeong Wook Song & Eun Young Lee, 2018. "Comorbidity, disability, and healthcare expenditure of ankylosing spondylitis in Korea: A population-based study," PLOS ONE, Public Library of Science, vol. 13(2), pages 1-13, February.
    2. Axel Svedbom & Johan Dalén & Moa Ivergård & Rebekah H. Borse & Christopher M. Black & Karin Luttropp & Sumesh Kachroo, 2020. "The value of persistence in treatment with subcutaneous TNF-alpha inhibitors for ankylosing spondylitis," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 21(1), pages 45-54, February.
    3. Aileen R. Neilson & Gareth T. Jones & Gary J. Macfarlane & Ejaz MI Pathan & Paul McNamee, 2022. "Generating EQ-5D-5L health utility scores from BASDAI and BASFI: a mapping study in patients with axial spondyloarthritis using longitudinal UK registry data," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 23(8), pages 1357-1369, November.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharmo:v:7:y:2023:i:3:d:10.1007_s41669-023-00404-3. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.